ALLO Allogene Therapeutics
- 2.900
- +0.140+5.07%
Allogene Therapeutics News
Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript
Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript
INFN, VYGR and AMSC Are Among After Hour Movers
Allogene Therapeutics Announces Pricing of $110 Million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T)
Allogene Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results.
Allogene Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results.
Allogene Therapeutics Q1 Loss Narrows, Revenue Declines
Allogene Therapeutics (ALLO) reported Q1 net loss Monday of $0.38 per diluted share, narrowing from $0.69 a year ago. Analysts polled by Capital IQ expected a loss of $0.41. Collaboration revenue for
Allogene Therapeutics | 10-Q: Quarterly report
Allogene Therapeutics Q1 2024 GAAP EPS $(0.38) Beats $(0.41) Estimate, Sales $22.000K Down From $30.000K YoY
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 44.93 percent increase over losses of
Allogene Therapeutics 1Q Loss/Shr 38c >ALLO
Allogene Therapeutics 1Q Loss/Shr 38c >ALLO
Press Release: Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update -- Cemacabtagene Ansegedleucel (Cema-Cel) -- Expanded CD19 Oncology Rights to Include all EU Member
8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersMonogram Orthopaedics (NASDAQ:MGRM) stock increased by 19.1% to $2.31 during Monday's pre-market session. The company's market cap stands at $73.1 million. Allarity Therapeutics (NASDAQ:ALLR) s
Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More
Allogene Therapeutics Awarded $15M Grant From California Institute For Regenerative Medicine To Advance Development Of Allogeneic CAR T In Renal Cell Carcinoma
$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in RCC an
Allogene Therapeutics Announces Q2 Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T)
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics with a Buy and maintains $10 price target.
Allogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic Advancements
Analysis
Price Target
No Data
